226 related articles for article (PubMed ID: 29605771)
1. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation.
Gonçalves A; Almeida L; Silva AP; Fontes-Ribeiro C; Ambrósio AF; Cristóvão A; Fernandes R
Biomed Pharmacother; 2018 Jun; 102():833-838. PubMed ID: 29605771
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats.
Gonçalves A; Marques C; Leal E; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Biochim Biophys Acta; 2014 Sep; 1842(9):1454-63. PubMed ID: 24769045
[TBL] [Abstract][Full Text] [Related]
3. Sitagliptin and the Blood-Retina Barrier: Effects on Retinal Endothelial Cells Manifested Only after Prolonged Exposure.
Jäckle A; Ziemssen F; Kuhn EM; Kampmeier J; Lang GK; Lang GE; Deissler H; Deissler HL
J Diabetes Res; 2020; 2020():2450781. PubMed ID: 32566677
[TBL] [Abstract][Full Text] [Related]
4. DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-κB activation.
Hu X; Liu S; Liu X; Zhang J; Liang Y; Li Y
Endocrine; 2017 Mar; 55(3):754-763. PubMed ID: 27612849
[TBL] [Abstract][Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibitor decreases abdominal aortic aneurysm formation through GLP-1-dependent monocytic activity in mice.
Lu HY; Huang CY; Shih CM; Chang WH; Tsai CS; Lin FY; Shih CC
PLoS One; 2015; 10(4):e0121077. PubMed ID: 25876091
[TBL] [Abstract][Full Text] [Related]
6. Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes.
Hernández C; Bogdanov P; Solà-Adell C; Sampedro J; Valeri M; Genís X; Simó-Servat O; García-Ramírez M; Simó R
Diabetologia; 2017 Nov; 60(11):2285-2298. PubMed ID: 28779212
[TBL] [Abstract][Full Text] [Related]
7. Protective effect of dipeptidyl peptidase-4 inhibitors in testicular torsion/detorsion in rats: a possible role of HIF-1α and nitric oxide.
Abdelzaher WY; Rofaeil RR; Ali DME; Attya ME
Naunyn Schmiedebergs Arch Pharmacol; 2020 Apr; 393(4):603-614. PubMed ID: 31773182
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.
Gonçalves A; Leal E; Paiva A; Teixeira Lemos E; Teixeira F; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
Diabetes Obes Metab; 2012 May; 14(5):454-63. PubMed ID: 22151893
[TBL] [Abstract][Full Text] [Related]
9. Vascular protection of DPP-4 inhibitors in retinal endothelial cells in in vitro culture.
Li H; Zhang J; Lin L; Xu L
Int Immunopharmacol; 2019 Jan; 66():162-168. PubMed ID: 30466028
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
Gault VA; Lennox R; Flatt PR
Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
[TBL] [Abstract][Full Text] [Related]
11. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-and interleukin-1beta-induced vascular permeability and angiogenesis in retinal endothelial cells.
Sheikpranbabu S; Ravinarayanan H; Elayappan B; Jongsun P; Gurunathan S
Vascul Pharmacol; 2010; 52(1-2):84-94. PubMed ID: 20006737
[TBL] [Abstract][Full Text] [Related]
12. The dipeptidyl peptidase 4 inhibitor sitagliptin improves oxidative stress and ameliorates glomerular lesions in a rat model of type 1 diabetes.
Marques C; Gonçalves A; Pereira PMR; Almeida D; Martins B; Fontes-Ribeiro C; Reis F; Fernandes R
Life Sci; 2019 Oct; 234():116738. PubMed ID: 31398418
[TBL] [Abstract][Full Text] [Related]
13. Prolonged effects of DPP-4 inhibitors on steato-hepatitic changes in Sprague-Dawley rats fed a high-cholesterol diet.
Pathak R; Kumar A; Palfrey HA; Stone KP; Raju NR; Gettys TW; Murthy SN
Inflamm Res; 2022 Jun; 71(5-6):711-722. PubMed ID: 35578028
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34⁺CXCR4⁺ cells in patients with type 2 diabetes.
Aso Y; Jojima T; Iijima T; Suzuki K; Terasawa T; Fukushima M; Momobayashi A; Hara K; Takebayashi K; Kasai K; Inukai T
Endocrine; 2015 Dec; 50(3):659-64. PubMed ID: 26209038
[TBL] [Abstract][Full Text] [Related]
15. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy.
Widlansky ME; Puppala VK; Suboc TM; Malik M; Branum A; Signorelli K; Wang J; Ying R; Tanner MJ; Tyagi S
Vasc Med; 2017 Jun; 22(3):189-196. PubMed ID: 28145158
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin alleviated myocardial remodeling of the left ventricle and improved cardiac diastolic dysfunction in diabetic rats.
Liu YS; Huang ZW; Wang L; Liu XX; Wang YM; Zhang Y; Zhang M
J Pharmacol Sci; 2015 Mar; 127(3):260-74. PubMed ID: 25837922
[TBL] [Abstract][Full Text] [Related]
17. DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice.
Kawasaki T; Chen W; Htwe YM; Tatsumi K; Dudek SM
Am J Physiol Lung Cell Mol Physiol; 2018 Nov; 315(5):L834-L845. PubMed ID: 30188745
[TBL] [Abstract][Full Text] [Related]
18. TNF-α signals through PKCζ/NF-κB to alter the tight junction complex and increase retinal endothelial cell permeability.
Aveleira CA; Lin CM; Abcouwer SF; Ambrósio AF; Antonetti DA
Diabetes; 2010 Nov; 59(11):2872-82. PubMed ID: 20693346
[TBL] [Abstract][Full Text] [Related]
19. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
Satoh-Asahara N; Sasaki Y; Wada H; Tochiya M; Iguchi A; Nakagawachi R; Odori S; Kono S; Hasegawa K; Shimatsu A
Metabolism; 2013 Mar; 62(3):347-51. PubMed ID: 23062489
[TBL] [Abstract][Full Text] [Related]
20. Effect of sitagliptin, a DPP-4 inhibitor, against DENA-induced liver cancer in rats mediated via NF-κB activation and inflammatory cytokines.
Jiang W; Wen D; Cheng Z; Yang Y; Zheng G; Yin F
J Biochem Mol Toxicol; 2018 Dec; 32(12):e22220. PubMed ID: 30218586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
